Compare Heron Therapeutics Inc (HRTX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Raymond James Financial, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Raymond James Financial, Inc. trades at $180.38 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 563.4× Heron Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | RJF | |
|---|---|---|
Market Cap | $61.47M | $34.63B |
Sector | Health | Financials |
52-Week High | $1.49 | $180.55 |
52-Week Low | $0.32 | $140.89 |
Enterprise Value | $168.21M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Raymond James Financial (RJF) trades at $180.34, up 0.7% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, with 2025 revenue at $13.84B and net income of $2.14B, supported by a P/E of 15.69 and net margin of 15.37%. Recent news highlights record Q3 2026 results and a golden cross formation, indicating positive momentum.
Outlook is positive due to consistent earnings outperformance and analyst buy ratings, but risks include volatile cash flows from investing activities and reliance on capital markets strength. The consensus price target of $183.75 suggests modest upside, with institutional interest shown by CalPERS' recent share acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
